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A bstract: A series o f ./V-phenyI-2-aza-spiro[4.5]cIecane-l,3-diones [III-V III], structurally related to the previ­
ously described /V-phenyl-3-aryIpyrrolidine-2,5-dione (1 1), was synthesized and tested for their anticonvulsant 
activity in the m axim um  electroshock seizure (M ES) and m etrazole seizure threshold (sc. M ET) tests. T he m ost 
potent o f the series were /V-(2-methylphenyl)-2-aza-spiro[4.5]decane-I,3-dione [III] and tY-O-methylphenyl)- 
2-aza-spiro [4.5]decane-l,3-dione [IV], which inhibited seizures in the MES and sc.M ET tests. On the other 
hand, as a preliminary assay we synthesized and tested fo r the anticonvulsant activity a new /V-substituted 8- 
phenyl-2-aza-spiro[4.5]decane-l,3-dione, containing either a benzyl or a cyclohexyl moiety [IX -X II] at the 
nitrogen atom. The obtained results showed that the presence and position o f the methyl group in the aryl ring 
[HI, IV] , as well as an cyclohexane moiety [XI, X II] connected with the imide nitrogen atom, played the essen­
tial role for anticonvulsant activity.
K eywords: anticonvulsant activity; N-phenyl substituted 2-aza-spiro[4.5]decane-l,3-diones; 8-phenyl-2-aza- 
spiro[4.5]decane-1,3-dione; spirosuccinimides
Previously, a great progress has been observed 
in research on new anticonvulsant drugs. The strate­
gy of searching for new anticonvulsant drugs is 
going parallel by seeking the explanation of mecha­
nism of action of the established drugs, as well as 
compounds being presently in the phase of clinical 
trials (1).
Anticonvulsant drugs are structurally different, 
which makes the structure-activity relationship stu­
dies difficult. In the past, several attempts were 
endeavored to propose a general pharmacophore for 
the different anticonvulsant drugs, and to find out 
some structural elements essential for the activity 
(2-4). In the search for the structure-activity rela­
tionships between the /V-phenyl derivatives of 
phthalimide, Vamecq et al. (5) demonstrated that the 
presence of a phtalimide pharmacophore, the methyl 
or chloro substituents at 2-position of the /V-phenyl 
ring, and the amine group situated in plane were 
essential for anticonvulsant activity. The structures 
o f /V-phenyl phtalimide derivatives with significant 
anti-MES activity are presented below:
O
O  H 3C  N H 2 
E D 50 = 8.0 mg/kg
E D 50 = 5.7 mg/kg
A study carried out by Scott et al. (6) on a group 
of spirosuccinimides showed the anticonvulsant activ­
ity for that type of compounds. Following investiga­
tions on the same group (7) and the crystallographic 
data of them (8) indicated an essential role of the cyclic 
system connected with the imide fragment through 
spiro carbon atom, regarding the influence of the com­
pounds of this type on the anticonvulsant activity.
In the recent years, we have synthesized a great 
number of compounds with the anticonvulsant activ­
ity by changing the substituents at positions-1,3 of 
pyrrolidine-2,5-dione ring. Some of these were 
effective in anti-MES and sc.MET tests (9-12). 
Their synthesis was based on some earlier results of 
crystallographic studies (13). These results indicated 
that in the group of 1,3-substituted pyrrolidine-2,5- 
dione derivatives, the aromatic system increased 
liphophilicity, while the carbonyl groups with an 
adequate electrostatic potential, and selected sub­




No. III IV V VI VII VIII
R 2-C H 3 3 -CH 3 4 -C H 3 2 -C H 3, 5-CI 3-CI 4-CI
Scheme 1.
Taking into account the above findings, in the 
present study we have synthesized a series of N- 
phenyl-2-aza-spiro[4.5]decane-l,3-dione [III-V III| 
with the methyl or chloro substituents at the aromat­
ic ring in respect to their anticonvulsant activity. On 
the other hand, we have undertaken studies con­
cerned with the introduction of the phenyl ring into 
4-position of the cyclohexane moiety to obtain a 
new class o f derivatives with supplementary aro­
matic area, and to determine whether these modifi­
cations would increase the anticonvulsant activity. 
Therefore, as a preliminary study, we synthesized 
some new A-substituted 8-phenyl-2-aza-spiro[4.51- 
decane-1,3-diones containing a benzyl or a cyclo- 
hexyl moiety [IX-XII] at the nitrogen atom, and we 
have tested them for anticonvulsant activity.
1-Carboxy-1-cyclohexane-acetic acid [I] and 
l-carboxy-l-(4-phenylcyclohexane)-acetic acid [II] 
were obtained by the methods previously described 
(6,14). Thus obtained acids were used to synthesize 
N-substituted 2-aza-spiro[4.5]decane-2,3-diones 
[III-VIII] and 8-phenyl-2-aza-spiro[4.5]decane- 
1,3-diones [IX-XII] by heating them with the appro­
priate substituted phenyl-, benzyl- o r cyclohexy- 
lamines. The synthesis o f compounds III-XII are 
presented in Schemes 1 and 2.
The 'H NMR spectra of the synthesized com­
pounds were also studied.
The 'H NMR spectra revealed a few characte­
ristic chemical shifts o f the investigated compounds. 
The chemical shifts o f imide protons in the N- 
phenyl-2-aza-spiro[4.5]decane-l ,3-dione derivatives 
IV, V, VII, VIII were displayed as singlets at 5 2.71 
ppm. The signal of imide protons of the 2-methyl 
derivatives III and VI appeared as a doublet at a 
2.74-2.76 ppm, J  = 4.4 Hz. The resonance signals of 
the methyl group appeared as a singlet at 8 2.12 ppm 
[III], 5 2.37 ppm [IV], 8 2.37 ppm [V] and 8 2.08
ppm [VI]. The chemical shifts of the cyclohexane 
ring in compounds III-VIII took the form of multi­
plets within the range of 8 1.32-1.96 ppm. The sig­
nals of aromatic protons for all the compounds of 
this series appeared as multiplets within the range of 
8 7.04-7.45 ppm.
The 'H NMR spectra of 8-phenyl-2-aza- 
sp iro[4.5]decane-l,3-dione derivatives IX-XII 
showed a few characteristic chemical shifts. The 
imide protons were observed as a singlet at 8 2.53 
ppm [IX], 8 2.51 ppm [X], 8 2.59 ppm [XI], and 8 
2.56 ppm [XII]. The resonance signal of the methy­
lene group, -CH2, appeared as a singlet at 8 4.64 
ppm [IX] and at 8 4.59 ppm [X], The 'H NMR spec­
tra of compounds X, XII showed protons of the - 
CH, group in the form of a singlet at 8 2.32 ppm [X] 
and a doublet at 8 1.04-1.07 ppm with the coupling 
constant./ = 7.15 Hz [XII]. The signals of aromatic 
protons for all the compounds were seen as multi­
plets within the range of 8 7.09-7.37 ppm. The pro­
tons of cyclohexane rings were observed as multi­
plets at 8 1.19-2.30 ppm. The resonance signals of 
the protons (PhCH) of cyclohexane rings appeared 
as a doublet within the range of 8 2.48-2.51 ppm ,./ = 
3.6 Hz [IX, X] and a doublet of triplets 8 2.60-2.66 
ppm, J  = 3.85 Hz for compounds XI, and at 8 2.41- 
2.45 ppm for compound XII. The 'H NMR spectra 
of XI and XII showed the proton (NCH) of cyclo­
hexane rings as a doublet of triplets 8 3.94-4.01 ppm 
J  = 3.85 Hz [XI] and 8 3.88-3.99 ppm /  =3.85 Hz 
[XII], The 'H NMR spectral data strongly supported 
the chemical structures of compounds III-XII.
EXPERIMENTAL  
Chemistry
Melting points (m.p.) were determined with an 
Electrothermal digital melting point apparatus, and
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I l l c ,6h I9n o 2 68 74.28 7.45 5.45 0.48 A
257.3 93-95’ 74.4 7.3 5.3 0.86 B
IV c ,„h I9n o 2 62 74.28 7.45 5.45 0.53 A
257.3 110-112* 74.3 7.5 5.6 0.89 B
V c I6h I9 n o 2 80 74.28 7.45 5.45 0.56 A
257.3 122-124 74.5 7.4 5.5 0.90 B
VI c I6h ,rc i n o 2 78 65.81 6.21 4.80 0.44A
291.8 205-207 65.7 6.1 4.7 0.89 B
VII C^H ^CINO , 82 65.04 5.82 5.06 0.45 A
277.8 144-150’ 64.9 5.6 4.9 0.85 B
V III C lsH lf) C1N02 78 65.04 5.82 5.06 0.43 A
277.8 153-155" 65.2 5.9 5.1 0.83 B
IX C,2H„N O , 76 79.35 6.96 4.21 0.46 A
333.4 109-111 79.0 6.8 4.1 0.89 B
X C l  1 N ( ) 62 79.38 7.24 4.02 0.57 A
348.5 129-131 79.6 7.0 3.9 0.90 B
XI c 2Ih 27 n o 2 68 77.61 8.37 4.31 0.76 A
325.5 175-177 77.5 8.5 4.5 0.90 B
XII c 22h 29 n o 2 73 77.95 8.62 4.13 0.72A
339.5 163-165 77.7 8.6 4.0 0.92 B
Solvent mixtures: A- ethyl acetate: n-hexane (3 : 7), B- chloroform : acetone ( 9 : 1 )  
T h e  Mp. values are in accord with ref. 15 
'T h e  Mp. values from ref. 15 are 137 1 C [VII], 140" C [VIII]
Table 2. 'H-NM R spectral data o f com pounds III-X II
Comp. 'H NMR 8 (ppm)/ CDC1,
I l l 1.33-1.96 (10H, m, cyclohexane), 2.12 (3H, s, -CH,) 2.74-2.76, (2H, d, imide, J  = 4.4 Hz), 7.04-7.33 
(4H, m, arom.).
IV 1.32-1.96 (10H, m, cyclohexane), 2.37 (3H, s, -CH,), 2.71 (2H, s, imide), 7.04-7.37 (4H, m, aromat).
V 1.31-1.96 (10H, m, cyclohexane), 2.37 (3H, s, -CH,), 2.71 (2H, s, imide), 7.12-7.27 (4H, m, arom.).
VI 1.32-1.98 (10H, m, cyclohexane), 2.08 (3H, s, CH,), 2.74-2.75 (2H, d, imide, J  = 4.6 Hz), 7.08-7.32 
(3H, m, arom.).
V II 1.31-1.95 (10H, m, cyclohexane), 2.72 (2H, s, imide), 7.19-7.42 (4H, m, arom.).
V III 1.32-1.95 (10H, m, cyclohexane), 2.72 (2H, s, imide), 7.23-7.45 (4H, m, arom.).
IX 1.51-2.30 (8H, m, cyclohexane), 2.49-2.51 (1H, d, cyclohexane J  = 3.6 Hz), 2.53 (2H, s, imide), 4.64 
(2H, s, -CH,), 7.17-7.37 (10H, m, arom.).
X 1.51-2.28 (8H, m, cyclohexane), 2.32 (3H, s, -CHj),  2.48-2.50 (1H, d, cyklohexane, J = 3.6 Hz), 2.51 
(2H, s, imide), 4.59 (2H, s, -CH,), 7.09-7.33 (9H, m, arom.).
XI 1.19-2.20 (18H, m, cyclohexane), 2.59 (2H,s, imide), 2.60-2.66 (1H, dt, cyclohexane, J  = 3.85 Hz), 
3.94-4.01 (1H, dt, cyclohexane, J  = 3.85 Hz), 7.18-7.33 (5H, m, arom.)
X II 1.04-1.07 (3H, d, -CH, J  = 7.15 Hz ), 1.31-2.14 (16H, m, cyclohexane), 2.41-2.45 (1H, dt, 
cyclohexane, J  = 3.85 Hz), 2.56 (2H, s, imide), 2.61-2.66 (1H, dt, cyclohexane, J  = 3.85 Hz), 3.88-3.99 
(1H, dt, cyclohexane,./ = 3.85 Hz), 7.15-7.30 (5H, m, arom.).
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IX-X
No. IX X XI XII
R 4-H 4 -C H 3 4-H 4 -C H 3
Scheme 2.
are uncorrected. The chemical structures' o f the 
obtained compounds was confirmed by elemental 
and spectral analyses. 'H NMR spectra (in CDC1,) 
were recorded with a Varian Mercury spectrometer 
operating at 300 MHz. Chemical shifts were report­
ed as parts per million (8 ppm) from (CH,)4Si (TMS) 
as an internal standard. Signal multiplicities are rep­
resented by the following abbreviations: s (singlet), 
d  (doublet), dt (double triplet), m (multiplet).
The elemental analyses for C, H, and N were 
found with an accuracy of +0.4% of the theoretical 
values.
The purity o f the compounds was checked by 
thin-layer chromatography (TLC) performed on 
Merck silica gel G F,,; aluminium sheets, using the 
developing systems: A) ethyl acetate : n-hexane (3 : 
7), B) chloroform : acetone (9 : 1). Spots were detec­
ted by their absorption under UV light, and by their 
visualization with 0.05 mol I, in 10 % HC1.
GENERAL PROCEDURE FOR THE PREPA­
RATION OF Ai-PHENYL-2-AZA-SPIRO[4.5]DECA- 
NE-l,3-DIONES [HI-VIII] AND /V-BENZYL- O R N- 
C Y C L O H E X Y L -8 -P H E N Y L -2 -A Z A -S P IR O -
[4.5]DECANE-1,3-DIONE DERIVATIVES [IX-XII]
To the suspension of either 1-carboxy-1-cyclo- 
hexane-acetic acid [I] or 1-carboxy-l-(4-phenyl- 
cyclohexane)-acetic acid [II] (0.02 mole) in 20 mL 
of water, the appropriately substituted phenyl-, ben­
zyl- or cyclohexylamine (0.02 mole) was gradually
added. The mixture was heated in an oil bath, and 
water was simultaneously distilled off. After the 
complete removal of water, the temperature of the 
reaction mixture rose up to 190-200’C, and next the 
temperature was maintained for 1.5 h. After cooling, 
the precipitated crude products were recrystallized 
from 96% ethanol. Physicochemical data, yields, ele­
mental analyses and R, values are presented in Table
1. 'H-NMR spectral data are shown in Table 2 .
It should be noted that com pounds III-V, 
VII and VIII were previously reported by El- 
Talbany (15) (however, no 'H NMR data are 
available), but none of them was tested for the 
anticonvulsant activity. Products VI and IX-XII 
are new ones.
Pharmacology
Preliminary pharmacological tests of the com­
pounds III-XII have been provided by the 
Antiepileptic Drug Development (ADD) Program, 
Epilepsy Branch, Neurological Disorders Program, 
National Institute o f the Neurological and 
Communicative Disorders and Stroke (NINCDS), 
Bethesda, by testing procedures which were reported 
earlier (16, 17). Phase I studies of the investigated 
compounds involved three testes: maximal elec­
troshock (MES), subcutaneous metrazole (sc. MET), 
and rotorod test for neurological toxicity (TOX). 
Phase I involved i.p. administration of the compounds 
as suspension in 0.5% methylcellulose, and it was a
Synthesis and anticonvulsant properties o f a series. 





0,5 h 4 h 0,5h
sc.M ETb
4 h 0,5 h
Tox‘
4 h
A S P 1
class.
30 0/1 0/1 0/1 0/1 0/4 0/2
I ll 100 3/3 0/3 0/1 0/1 0/8 0/4 1
300 1/1 0/1 4/5 0/1 2/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
IV 100 0/3 0/3 3/5 0/1 1/8 0/4 1
300 0/1 0/1 1/1 1/1 4/4'4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
V 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 1/414 0/2
10 0/1 0/1 0/1 0/1 0/4 0/2
VI 30 0/3 0/3 0/1 0/1 0/8 0/4 3
100 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
VII 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 0/1 0/1 4/5 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
VIII 100 0/3 0/3 0/1 0/1 5/8 0/4 3
300 - - - - 4/45 -
30 0/1 0/1 0/1 0/1 0/4 0/2
IX 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 j 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
X 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 0/1 0/1 2/5 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XI 100 0/3 0/3 0/1 2/5 1/8 0/4 1
300 0/1 0/1 2/5 0/1 1/4 1/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XII 100 0/3 0/3 0/1 2/5 5/8 0/4 1
300 0/1 0/1 2/5 0/1 2/4 0/2
'"Maximal electroshock test (num ber o f animals protected/ number of animals tested); '"Subcutaneous m etrazole test; c’Rotorod toxicity 
(number o f animals exhibiting toxicity/ number of animals tested); '"The classification are as follows: 1-anticonvulsant activity at doses 
lOOmg/kg or less; 2-anticonvulsant activity at doses greater than lOOmg/kg; 3-compound inactive at 300mg/kg.
Response comments: "Death following clonic seizure, Uunable to grasp rotorod.
qualitative assay involving a small number of mice 
(1-4) at a dose levels of 30, 100, and 300 mg/kg- The 
compounds were classified as the following cate­
gories: anticonvulsant activity at 100 mg/kg or less 
(class 1), anticonvulsant activity at doses greater than 
100 mg/kg (class 2), compounds inactive at 300 
mg/kg (class 3).The results are shown in Tabjle 4.
RESULTS
/V-phenyl-2-aza-spiro[4.5]decane-l ,3-diones 
III-V III exhibited some anticonvulsant properties
in the phase I screening project or were inactive. In 
this series of compounds, /V-(2-methylphenyl)-2- 
aza-spiro[4.5]decane-l,3-dione III  was active at a 
dose of 100 mg/kg (3/3 animals protected at 0.5 h) 
and 300 mg/kg (1/1 animals protected at 0.5 h ) in 
the MES test and at a dose of 300 mg/kg (4/5 ani­
mals protected at 0.5 h) in the sc. MET test. The 3- 
methyl analogue IV was also active at a dose of 100 
mg/kg (3/5 animals protected at 0.5 h) and 300 
mg/kg (1/1 animals protected at 0.5 and 4 h) in the 
sc. MET test. Substitution of the methyl group in 4- 
position of the phenyl ring of compound V, as well
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as introduction of the chloro substituent into 5-posi- 
tion of compound VI made them inactive in both 
tests. 3-Chloro derivative VII was marginally active 
at a dose of 300 mg/kg (4/5 animals protected at 0.5 h) 
in the sc.MET. 4-Chloro analogue VIII was inac­
tive, and at dose of 300 mg/kg it caused the death of 
animals following clonic seizures.
In the series o f 8-phenyl-2-aza-spiro-
[4.5]decane-l ,3-diones, the introduction of a supple­
mentary aromatic ring into 4-position of the cyclo- 
hexane fragments, and the conversion of the N- 
phenyl- to V-benzyl- substituents in IX, X did not 
improve their anticonvulsant activity. Compound X 
with the methyl group at 4-position of the phenyl 
ring showed a protective effect towards seizures at a 
dose of 300 mg/kg (2/5 animals protected at 0.5 h) 
in the sc. MET test. The ¡V-cyclohexyl derivatives 
XI and XII were both active in the sc. MET test at a 
doses of 100 mg/kg (2/5 animals protected at 4 h) 
and 300 mg/kg (2/5 animals protected at 0.5 h).
In the neurological toxicity screening, the test­
ed compounds III, V, VI, VII, IX, and X were non­
toxic at a dose of 100 mg/kg. The mice were unable 
to grasp the rotorod after the administration of com ­
pounds IV (300 mg/kg at 0.5 h), and V (300 mg/kg 
at 0.5 h).
In conclusion, our study has shown that in the 
series of /V-phenyl-2-aza-spiro[4.5 ]decane-1,3-dione 
derivatives, a significant role for the anticonvulsant 
activity depends on the kind and position of the sub­
stituents attached to the phenyl ring. The methyl 
group in 2- or 3-position of the phenyl ring increases 
the anticonvulsant activity [III, IV]. The presence of 
the chloro substituents makes the compounds either 
less potent [VII] or inactive [VI, VII]. On the other 
hand, among the new preliminary series of V-substi- 
tuted 8-phenyl-2-aza-spiro[4.5]decane-1,3-dione 
derivatives, there are compounds with the anticon­
vulsant activity, namely V-cyclohexyl derivatives 
[XI, XII], On the grounds of these findings we 
intend to synthesize a new series of V-cyclohexyl-8- 
phenyl-2-aza-spiro[4.5]decane-l,3-diones with vari­
ous substituents at the cyclohexyl ring, as com­
pounds with the potential anticonvulsant activity. 
The results of this study will be published soon.
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